Bomai Medical's ChiNext IPO has been inquired, focusing on the high-performance vascular intervention medical device field.

On January 8th, Guangdong Boi Medical Technology Co., Ltd. (Boi Medical) applied for a change in the status of the listing review on the Shenzhen Stock Exchange's ChiNext board to "Under Inquiry," with China International Capital Corporation Limited as its sponsor, aiming to raise 1.7 billion yuan. According to the prospectus, Boi Medical focuses on the research, production, and global sales of high-performance vascular interventional medical devices, and is a leading provider of complex vascular disease intervention treatment solutions in the global industry in terms of technology and products. It is also a leading research and production enterprise in the field of domestic vascular intervention balloon catheters. In terms of product system construction, the company has developed a comprehensive product matrix covering multiple treatment scenarios, with over 50 product series. The application areas of the products include coronary intervention, peripheral intervention, neuro intervention, hemodialysis access intervention, and intervention accessories, which include various general balloon catheters, functional balloon catheters, drug-eluting balloon catheters, interventional guidewires and catheters, various thrombus processing devices, calcification processing devices, energy therapy devices, and other core product lines that can fully meet the diverse needs of clinical intervention for complex vascular diseases. In terms of research and production layout, the company focuses on global resource integration and capacity assurance. It has established five research and development centers and laboratories worldwide, continuously promoting core technology iteration and innovative product development. It has established four production bases to ensure product scalability and high-quality supply, while also setting up three international operation centers to provide efficient operational support and service guarantees for global market expansion. In terms of market coverage, the company's products have successfully penetrated over 100 countries and regions at home and abroad, serving tens of thousands of hospitals and medical centers worldwide. With stable product performance, systematic treatment solutions, and professional technical support, it has established a good brand image in the domestic and international vascular intervention medical device market, gradually building a global market layout and customer service network. The company has long adhered to the "innovation + scalability + internationalization" tripartite business development strategy, and has grown into a multinational platform enterprise with rapid development and important industry influence in the global vascular intervention industry. The core development concept of the company's technological innovation and global industrialization is "support originality in China, benefit global patients." Since its establishment, the company has maintained a high level of research and development investment, building a complete and efficient research and development talent team and IPD product development system. Relying on core research institutions such as the Guangdong Provincial Vascular Intervention Treatment Technology and Equipment Engineering Research Center, the Dongguan Vascular Intervention Medical Device Research and Development Key Laboratory, and CNAS Laboratory, the company has achieved multiple global breakthroughs in product technology, core processes, and other fields through global industrial-academic research collaboration and medical-engineering innovation cooperation. As of the date of the prospectus signing, the company has launched seven globally pioneering or uniquely innovative products, and as the exclusive completion unit, it has won the second prize for scientific and technological progress in Guangdong Province for the year 2020. In addition, 12 products have been recognized as Guangdong Province's outstanding high-tech products, and more than 80 domestic and international invention patents have been granted, laying a solid foundation for continuous innovation. As a leading company in the field of vascular intervention medical devices, Boi Medical occupies a leading position in the market due to its technological advantages and scalable production capacity in products such as balloon catheters. According to Frost & Sullivan data, by 2024, Boi Medical will become the fourth in the Chinese coronary artery balloon dilatation catheter market with a 9.6% market share and the first in domestic brands; and the fifth in the Chinese peripheral artery balloon dilatation catheter market with a 4.7% market share. In terms of finances, in the years 2022, 2023, 2024, and January to June 2025, the company achieved operating incomes of approximately 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan respectively. During the same period, the net profits were -36.06 million yuan, 25.99 million yuan, 76.78 million yuan, and 35.64 million yuan respectively.